For the Quarter Ending September 2025
APAC
• In India, the Clopidogrel Price Index fell by 6.56% quarter-over-quarter, due to oversupply and weak demand.
• The average Clopidogrel price for the quarter was approximately USD 42524.99/MT as reported by spot indications.
• Clopidogrel Spot Price softened during the quarter as aggressive destocking and export offers pressured domestic quotations lower.
• Clopidogrel Production Cost Trend improved with lower feedstock costs, allowing suppliers to offer discounted volumes.
• Clopidogrel Demand Outlook remained cautious as formulation buyers delayed replenishment, limiting absorption of elevated inventories.
• Clopidogrel Price Forecast indicates modest seasonal recovery ahead, supported by maintenance shutdowns and festival-driven buying.
• Clopidogrel Price Index volatility reflected INR depreciation and freight reductions, influencing market sentiment and caution.
• Export demand and production diversions tightened domestic availability, supporting upward pressure on spot and contract prices.
Why did the price of Clopidogrel change in September 2025 in APAC?
• Elevated domestic manufacturing and PLI-driven oversupply created inventory glut, exerting downward pressure on September quotations.
• Reduced downstream purchasing and cautious formulation procurement limited demand, preventing absorption of excess market volumes.
• Lower feedstock costs and improved logistics reduced production and freight expenses, enabling sellers to cut prices strategically.
North America
• Clopidogrel Price Index exhibited a moderate decline quarter-over-quarter, influenced by fluctuating inventory positions and subdued offtake from downstream pharmaceutical formulators.
• Average Clopidogrel Price trended lower during the period, reflecting competitive offers amid cautious procurement across the U.S. and Canadian markets.
• Clopidogrel Spot Price softened as producers prioritized export commitments and local distributors reduced inventories to manage cash flow.
• Clopidogrel Production Cost Trend improved slightly with easing input costs and better plant operating rates, though energy price fluctuations created mixed cost dynamics.
• Clopidogrel Demand Outlook remained steady but cautious, as buyers awaited clearer signals from prescription drug demand and hospital purchasing cycles.
• Clopidogrel Price Forecast indicates a potential moderate recovery in the upcoming quarter, supported by scheduled production turnarounds and improved retail demand.
• Clopidogrel Price Index Volatility reflected changes in crude oil-linked feedstocks and domestic logistics costs, shaping short-term sentiment.
• Export and Import Flow Adjustments influenced supply distribution, occasionally tightening availability in certain states and supporting marginal price stabilization.
Europe
• Clopidogrel Price Index weakened slightly during the quarter amid steady supply inflows from regional and overseas producers, alongside mild demand contraction from formulators.
• Average Clopidogrel Price remained under pressure as distributors adjusted inventory levels following lower-than-expected pharmaceutical offtake in major EU markets.
• Clopidogrel Spot Price displayed mixed sentiment, with southern European markets facing weaker demand while central regions observed modest restocking.
• Clopidogrel Production Cost Trend was aided by lower raw material prices, although high utility and energy expenses continued to constrain margin recovery.
• Clopidogrel Demand Outlook suggested cautious optimism ahead, with hospitals and drug manufacturers planning moderate restocking before the winter season.
• Clopidogrel Price Forecast anticipates stable-to-firm pricing in the near term, supported by seasonal demand recovery and balanced production schedules.
• Clopidogrel Price Index Volatility was shaped by exchange rate fluctuations (EUR vs. USD) and varying freight conditions across intra-EU trade routes.
• Export Market Sentiment stayed mixed, as stronger Asian competition limited outbound sales while localized shortages lent some domestic price support.
For the Quarter Ending June 2025
North America
• The overall trend for Clopidogrel Bisulfate spot price in North America during Q2 2025 exhibits a downward trajectory, mirroring the declining pattern observed in the Indian market. Spot prices softened steadily through June 2025, ending the quarter at levels below peak Q1 values.
• The Clopidogrel Bisulfate price forecast for the next quarter indicates continued downward pressure due to the spillover effects of India’s surplus supply and easing production costs, supporting a bearish outlook on pricing strategy in North America.
• Clopidogrel Bisulfate Production cost trends within the quarter reflected modest reductions, driven by lowered raw material costs influenced by improved logistics and supply chain conditions originating from key bulk drug exporters such as India.
• Clopidogrel Bisulfate Demand outlook within the quarter remained cautious; while cardiovascular disease prevalence supports steady Clopidogrel consumption, procurement cycles elongated as buyers anticipated further price corrections.
• June 2025 witnessed notable price softening, triggered by Indian exporters aggressively pricing excess Clopidogrel APIs, which pressured North American manufacturers to adjust their pricing and inventory strategies.
• Regulatory scrutiny and compliance requirements continued to impose operational costs, moderating gains from lower production expenses and constraining manufacturers’ margin improvements.
• The competitive landscape saw intensified activity from generic players capitalizing on the lower spot price environment to expand market share.
• Supply tightness experienced earlier in the year eased due to improved API availability, slowing the urgency of stockpiling among distributors and formulators.
• Contract manufacturing organizations (CMOs) responded by enhancing manufacturing flexibility to adapt to fluctuating demand and pricing dynamics in the quarter.
• Forward procurement strategies became increasingly data-driven, with buyers leveraging market intelligence to optimize purchase timing amid volatile price movements.
APAC
• Clopidogrel Bisulfate spot price in APAC experienced a mixed trend in Q2 2025, with an overall marginal decline averaging approximately -0.31% quarter-over-quarter. Prices trended downward by June, reflecting influences from the Indian market’s significant supply expansion and inventory liquidation.
• The Clopidogrel Bisulfate price forecast for the next quarter suggests further downward pressure in APAC due to persistent supply glut and cautious demand behavior among end-users constrained by tighter healthcare budgets.
• Clopidogrel Bisulfate Production cost trends within the quarter benefited from improved raw material availability and reduced energy expenses, particularly in leading manufacturing hubs across India and China.
• Clopidogrel Bisulfate demand outlook within the quarter was tempered by strategic procurement pauses, with buyers balancing baseline cardiovascular demand against an oversupplied market and better pricing options.
• June 2025 saw a pronounced dip in spot prices as excess API inventory from Indian producers entered regional export markets, pressuring local manufacturers’ pricing strategies.
• Input cost deflation was a key driver in the production cost trend, with fermentative intermediates and solvents declining in price, enabling more competitive pricing for Clopidogrel APIs.
• Supply dynamics were affected by regulatory reforms and environmental audits in China, which constrained alternative API sources but were offset by Indian production capacity gains.
• Pharmaceutical players in the region adjusted inventories conservatively, preferring spot market purchases amid price weakness rather than long-term contract commitments.
• Export demand from Southeast Asian countries remained positive but slowed down due to buyers’ cautious stance in light of anticipated price falls.
• Manufacturing investments focused on capacity optimization and compliance enhancements to maintain quality standards while managing cost pressures.
Europe
• In Europe, the Clopidogrel Bisulfate spot price showed a downward trend in Q2 2025, consistent with the Indian market’s decline, with an average price decreasing considerably. By June, prices had weakened further due to eased pressure from global supply surpluses.
• The Clopidogrel Bisulfate price forecast for the next quarter indicates potential stabilization but limited upside, as European buyers adjust to increased API availability and stable production costs.
• Clopidogrel Bisulfate Production cost trends remained relatively stable, supported by competitive sourcing from Indian and regional suppliers, combined with efficient manufacturing operations adhering to stringent EU regulatory standards.
• Clopidogrel Bisulfate Demand outlook within the quarter was steady yet cautious, reflecting tight budget controls in European healthcare systems and moderate growth in chronic cardiovascular patient populations.
• June 2025 marked a period of increased buyer price sensitivity, with contract formulators reluctant to replenish large inventories amid low spot prices.
• The impact of Indian manufacturers’ stock liquidations was strongly felt across European markets, creating downward pressure on local market prices.
• Regulatory compliance costs remained a significant factor but were effectively managed through technological upgrades and streamlined quality assurance processes.
• European distributors leveraged the favorable price environment to optimize supply chain efficiencies, emphasizing just-in-time inventory strategies.
• Market competition intensified as generic manufacturers and biosimilar producers sought to capitalize on the reduced API cost base.
• Forward-looking procurement strategies integrated advanced analytics to forecast demand volatility and price movements in the evolving regulatory landscape.
For the Quarter Ending March 2025
North America
During the first quarter of 2025, the Clopidogrel Bisulfate API market in North America demonstrated notable fluctuations, shaped by shifting demand fundamentals, logistical adjustments, and currency-related influences. In January, prices experienced a marked decline as pharmaceutical manufacturers and buyers within the region scaled back procurement due to regulatory ambiguities and subdued end-user demand.
Inventory optimization strategies and a cautious approach towards raw material purchasing led to restrained capacity utilization rates, while downstream manufacturers focused on working capital management amid macroeconomic uncertainties. The market remained oversupplied through January, further pressuring pricing. However, February marked a decisive shift as downstream pharmaceutical procurement improved on account of seasonal increases in demand for cardiovascular medications, which Clopidogrel Bisulfate supports.
Supply-demand dynamics stabilized as importers actively replenished inventories to mitigate future logistical risks. By March, with inventory levels balanced and pharmaceutical sector consumption steady, the market maintained a cautious but optimistic tone. Overall, Q1 2025 reflected a volatile pricing environment in North America, with early-quarter bearishness progressively offset by late-quarter market corrections and improved downstream purchasing.
Asia Pacific
The Clopidogrel Bisulfate API market in the Asia Pacific region experienced a highly dynamic pricing pattern over the first quarter of 2025. January commenced on a bearish note, characterized by significant price depreciation driven by weak pharmaceutical sector demand and ample inventory levels carried forward from the previous quarter. While manufacturing activity within the broader pharmaceutical sector remained robust, improved vendor performance and efficient raw material availability prevented supply-side disruptions, contributing to oversupply conditions.
Buyers in key export destinations withheld large-scale procurement, anticipating further price reductions amidst ongoing macroeconomic headwinds. However, February ushered in a sharp price rebound, supported by a noticeable recovery in downstream demand as procurement cycles restarted following seasonal inventory adjustments. The depreciation of regional currencies against the U.S. dollar further strengthened export prices, creating favourable conditions for local suppliers. Policy reforms, including exemptions on certain medicinal products, also enhanced trading sentiments within the pharmaceutical industry.
Major therapeutic areas, particularly cardiovascular segments, witnessed strong demand growth, directly benefiting Clopidogrel Bisulfate’s price recovery. By March, while overall demand moderated, stable procurement and controlled supply conditions maintained steady pricing levels. Consequently, Q1 2025 in the Asia Pacific market closed with a marginal recovery after early-quarter corrections.
Europe
In Europe, the Clopidogrel Bisulfate API market throughout Q1 2025 was marked by a sequential pricing pattern influenced by fluctuating demand cycles and global pharmaceutical sector dynamics. Prices in January declined considerably as downstream pharmaceutical manufacturers implemented stringent inventory control measures amidst regulatory uncertainties and weak export order flows. This was compounded by steady manufacturing output and adequate raw material availability, creating an oversupplied environment that pressured prices downward.
Despite stable input costs, oversupply and subdued purchasing led to deferred procurement activity. February, however, signalled a turning point as pharmaceutical demand increased across several therapeutic categories, particularly for cardiovascular medicines, resulting in a noticeable uptick in market transactions. Furthermore, improved trade dynamics and government support measures for healthcare infrastructure enhanced procurement activity within the pharmaceutical sector. By March, market fundamentals largely stabilized, with inventory rationalization efforts balancing supply and demand. Overall, Q1 2025 in Europe reflected a price trajectory of early-quarter weakness followed by mid-quarter recovery and late-quarter consolidation, shaped by fluctuating demand and external cost drivers.
For the Quarter Ending December 2024
North America
The U.S. Clopidogrel Bisulfate market experienced fluctuating trends in the fourth quarter of 2024, driven by a combination of supply chain challenges, seasonal demand patterns, and economic pressures.
October saw a steady rise in Clopidogrel Bisulfate prices, supported by increased demand from the pharmaceutical sector to meet heightened production needs ahead of the flu season. Elevated transportation costs and logistical bottlenecks, particularly for imports from Asian and European suppliers, compounded supply-side challenges. Additionally, the rising cost of key raw materials, such as Clopidogrel Bisulfate, further amplified production expenses for domestic manufacturers. In November, the market shifted as prices began to stabilize due to improved supply chain efficiency and efforts by major suppliers to clear excess inventories. Aggressive pricing strategies during the holiday season, combined with reduced export demand, moderate upward price pressures. Despite this, market players remained cautious, with concerns over potential disruptions from port negotiations and looming tariff adjustments impacting imports from key global markets.
By December, a combination of reduced procurement activity from downstream sectors and higher inventories among the traders drove prices downward. High inventory levels led to intensified competition among suppliers, while demand remained largely stagnant. Overall, the quarter closed with cautious market sentiment and increased focus on managing inventory levels to offset prolonged price declines.
APAC
Throughout the final quarter of 2024, the Indian Clopidogrel Bisulfate market exhibited a mixed performance, marked by an initial price surge in October followed by a correction in November. Early in the quarter, export prices climbed due to higher procurement within the end-users. Supply-side constraints, higher production costs, and logistical challenges—such as elevated freight rates and delays during the festive period—intensified upward price pressures, creating a bullish trend. Tight inventories and rising demand elasticity further fueled this momentum, with prices reflecting a strained market balance. This trend continued until the final week of November. By December, however, the market began to stabilize. Reduced demand from key sectors, particularly pharmaceuticals and healthcare, coupled with improved supply chain efficiency, eased pricing pressures. Buyers adopted cautious procurement strategies to manage inventory effectively, mitigating the impact of earlier price hikes. Despite the Indian rupee's depreciation, which raised import costs, local producers absorbed some of these pressures to remain competitive, fostering gradual market correction. As a result, the quarter concluded on a stable note, with exporters prioritizing prudent pricing strategies to navigate currency volatility. As inventory levels aligned with demand and exchange rate fluctuations subsided, the Clopidogrel Bisulfate market displayed resilience and adaptability, setting a stable foundation for future growth.
Europe
In the fourth quarter, the Clopidogrel Bisulfate market in Germany experienced significant fluctuations influenced by supply-demand imbalances and varying economic conditions. Initially, prices rose due to raw material shortages and higher production costs. Steady downstream demand supported market sentiment during this phase. However, as the quarter advanced, softer market conditions emerged, characterized by excess inventory accumulation. This was due to reduced distributor purchasing and cautious procurement practices. The depreciation of the Euro against the USD further complicated the situation, raising import costs and undermining buyer confidence. Suppliers responded with aggressive pricing strategies, including discounts to clear stock and sustain market share. By December, the market shifted toward a downward trend, driven by reduced purchasing and higher inventories which was pre-holiday stockpiling and favorable production conditions witnessed in the past months. Despite stable consumption in key sectors, a lack of new demand hindered price recovery. Suppliers focused on inventory management, and increasingly competitive pricing pointed to a bearish outlook, expected to persist until demand for fundamentals strengthens.
